Thaiss Friedrich
Universitätsklinikum Hamburg Eppendorf, Zentrum Innere Medizin und Transplantation, III. Medizinische Klinik und Poliklinik, Hamburg, Germany.
Atheroscler Suppl. 2009 Dec 29;10(5):133-6. doi: 10.1016/S1567-5688(09)71828-8.
Pre-emptive living kidney transplantation is the best choice of therapy to treat patients with advanced renal insufficiency. Unfortunately in up to one third of all cases kidney donation was refused due to blood group incompatibility. Limitations in donor availability for kidney transplantation therefore require that ABO-incompatible transplantation is safely established. This has changed when a new protocol was introduced in Stockholm, Sweden, in 2001. Almost 400 ABO-incompatible transplantations have since been performed in more than 20 centers with this protocol in Europe. ABO-incompatible living kidney transplantation can now be offered to our patients with advanced kidney disease as a safe procedure. To get more insight into the role ABO-incompatible organ transplantation might play in the near future transplantation centers currently involved in these processes should share their data to answer the unresolved issues we are concerned.
预先活体肾移植是治疗晚期肾功能不全患者的最佳治疗选择。不幸的是,在所有病例中,高达三分之一的肾脏捐赠因血型不相容而被拒绝。因此,肾移植供体可用性的限制要求安全地开展ABO血型不相容移植。2001年瑞典斯德哥尔摩引入一项新方案后,情况发生了变化。自那时起,欧洲20多个中心已依据该方案进行了近400例ABO血型不相容移植。现在,ABO血型不相容活体肾移植作为一种安全的手术,可以提供给患有晚期肾病的患者。为了更深入了解ABO血型不相容器官移植在不久的将来可能发挥的作用,目前参与这些过程的移植中心应分享数据,以解答我们所关注的未解决问题。